Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in TEM.
← Back to Free Index

TEM

Analysis as of: 2026-07-14
Tempus AI, Inc.
Tempus AI sells genomic diagnostics, clinical workflow software, and governed data products to physicians, health systems, and biopharma customers.
ai biotech enterprise healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

A credible mix-shift path, not a pure AI bet
The company already has real diagnostics scale, and the upside comes from turning that scale into governed data, evidence, and workflow revenue with better economics. The opportunity is meaningful, but the proof points are reimbursement, embed depth, and cash conversion rather than narrative alone.

Analysis

Thesis
Tempus has a credible path to grow faster than a normal diagnostics company because each clinical test can feed higher-value data, evidence, and workflow revenue; if management converts that loop into durable paid usage while improving reimbursement and margins, equity value can compound materially over five years.
Last Economy Alignment
AI makes Tempus’ governed clinical data, regulated testing, and workflow embeds more valuable, but reimbursement, privacy, and trust constraints keep it from being a pure AI scarcity asset.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.6x (from 5 most recent analyses)
Reasoning
The upside case does not require Tempus to become a pure software company. It requires diagnostics to keep growing, data and applications to outgrow the base, and workflow tools to become budgeted parts of care and research. That combination can justify a higher but still disciplined revenue multiple and a solidly above-market equity compounding path.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is not whether Tempus has products; it does. The real risk is economic conversion: can it turn diagnostics volume, governed data, and workflow presence into recurring higher-margin revenue before reimbursement friction, privacy scrutiny, or financing needs limit the re-rating. That keeps the upside attractive but prevents a pure-software style underwriting case.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.65
They control regulated tests, governed clinical data, and workflow touchpoints that become more useful as AI gets cheaper. The risk is that privacy rules, reimbursement gates, or larger platforms capture the trust and workflow layer before Tempus fully does.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$66.06
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case